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Abstract
Background: The overall influence of gene interaction in human disease is unknown. In cystic fibrosis (CF) a single
allele of the cystic fibrosis transmembrane conductance regulator (CFTR-ΔF508) accounts for most of the disease. In
cell models, CFTR-ΔF508 exhibits defective protein biogenesis and degradation rather than proper trafficking to the
plasma membrane where CFTR normally functions. Numerous genes function in the biogenesis of CFTR and
influence the fate of CFTR-ΔF508. However it is not known whether genetic variation in such genes contributes to
disease severity in patients. Nor is there an easy way to study how numerous gene interactions involving CFTR-ΔF
would manifest phenotypically.
Methods: To gain insight into the function and evolutionary conservation of a gene interaction network that
regulates biogenesis of a misfolded ABC transporter, we employed yeast genetics to develop a ‘phenomic’ model,
in which the CFTR-ΔF508-equivalent residue of a yeast homolog is mutated (Yor1-ΔF670), and where the genome
is scanned quantitatively for interaction. We first confirmed that Yor1-ΔF undergoes protein misfolding and has
reduced half-life, analogous to CFTR-ΔF. Gene interaction was then assessed quantitatively by growth curves for
approximately 5,000 double mutants, based on alteration in the dose response to growth inhibition by oligomycin,
a toxin extruded from the cell at the plasma membrane by Yor1.
Results: From a comparative genomic perspective, yeast gene interactions influencing Yor1-ΔF biogenesis were
representative of human homologs previously found to modulate processing of CFTR-ΔF in mammalian cells.
Additional evolutionarily conserved pathways were implicated by the study, and a ΔF-specific pro-biogenesis
function of the recently discovered ER membrane complex (EMC) was evident from the yeast screen. This novel
function was validated biochemically by siRNA of an EMC ortholog in a human cell line expressing CFTR-ΔF508.
The precision and accuracy of quantitative high throughput cell array phenotyping (Q-HTCP), which captures tens
of thousands of growth curves simultaneously, provided powerful resolution to measure gene interaction on a
phenomic scale, based on discrete cell proliferation parameters.
Conclusion: We propose phenomic analysis of Yor1-ΔF as a model for investigating gene interaction networks that
can modulate cystic fibrosis disease severity. Although the clinical relevance of the Yor1-ΔF gene interaction
network for cystic fibrosis remains to be defined, the model appears to be informative with respect to human cell
models of CFTR-ΔF. Moreover, the general strategy of yeast phenomics can be employed in a systematic manner
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to model gene interaction for other diseases relating to pathologies that result from protein misfolding or
potentially any disease involving evolutionarily conserved genetic pathways.
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Background
Since release of the human genome sequence, genome-
wide association studies (GWAS) and other advances in
genomic technology have challenged simplistic notions of
the genetic basis of human disease. Even Mendelian dis-
ease phenotypes are now thought to be driven by complex
genetic relationships [1]. For example, modifier genes can
influence the severity of cystic fibrosis [2]. However, the
influence on disease contributed by multi-locus, combina-
tion-specific pairs of allelic variants remains largely
unmapped and uncharacterized biologically. Moreover,
most disease traits are non-Mendelian (that is, ‘complex’
traits), where expression of the phenotype involves multi-
ple different gene activities, none of which is individually
required or accounts for a large fraction of heritability
[3,4]. Thus Mendelian and complex traits can be seen as
different ends of the same continuum in which multiple
genetic and environmental effects impact disease risk and/
or severity in a combination-dependent manner. It is pre-
sumed that in some genetic or environmental contexts
particular variant alleles are phenotypically expressed, and
in other contexts they are buffered. However, whether
principles for disease variation can be deduced through
systematic analysis of gene-gene interaction remains
unknown [5]. In this study we developed a yeast model of
gene interaction for a clinically relevant disease mutation,
CFTR-ΔF508, to investigate whether it can potentially
serve as a useful tool to better understand the genetic
complexity underlying the human disease, cystic fibrosis
[6]. Saccharomyces cerevisiae is a workhorse for funda-
mental biology, but the extent to which experimental
models of gene-gene interaction employing an endogen-
ous yeast cellular context could provide disease-relevant
insight via gene homology is unknown [5]. To investigate
this question, we applied the Q-HTCP method to systema-
tically query the yeast genome for modifiers of a specific
phenotype resulting from Yor1-ΔF670, and provide evi-
dence validating this yeast phenomic (genome-wide analy-
sis of phenotypic modification due to gene interaction)
model for CFTR-ΔF508, the most prevalent human allele
causing cystic fibrosis [7].
To model the evolutionarily conserved network of gene
interaction involving CFTR-ΔF508, we introduced the
homologous yeast ABC transporter, Yor1-ΔF670 [8,9],
into the library of non-essential yeast gene deletion
strains [10-12], and used Q-HTCP [13,14] to measure
the influence of gene-gene interactions on cell prolifera-
tion in the presence of oligomycin, a toxin extruded from
cells by Yor1. From a drug discovery perspective, protein
regulators of CFTR-ΔF biogenesis represent novel tar-
gets, and cell culture experiments indicate such targets
are numerous [15,16]. Many of these regulators are evo-
lutionarily conserved, thus a quantitative systems level
model of a gene interaction network model derived from
yeast could complement human and animal studies [17].
From a systems biology perspective, the quantitative
description of a gene network that modulates biogenesis
of a misfolded ABC transporter could provide useful
insight for understanding the phenotypic complexity of
cystic fibrosis in association with human genetic data,
and might similarly aid study of other diseases related to
protein misfolding. If successful for cystic fibrosis, the
same general strategy of yeast phenomic modeling should
be applicable to derive understanding about disease com-
plexity involving any conserved cellular pathway.
Methods
Yeast strains
Deletion mutants were from the MATa collection, cre-
ated by the Saccharomyces Genome Deletion Project
[18], and obtained from Open Biosystems. The query
strain background for double mutant construction was
15578-1.2b [10]. The R1116T mutation (Figure 1) was
introduced into pSM2056 (yor1-ΔF670-HA-GFP::URA3
integrating vector) [19] by Quik Change mutagenesis
(Stratagene) to create plasmid pRL026. This vector was
used as a template to amplify a PCR fragment corre-
sponding to yor1-ΔF670/R1116T-HA-GFP-3’UTR which
was combined with another PCR fragment encoding the
NATMX cassette flanked by further YOR1 3’UTR
sequence by splice overlap PCR. The full product (yor1-
ΔF670/R1116T-HA-GFP-3’UTR-NATMX-3’UTR) was
transformed into yeast and selected for on media con-
taining nourseothricin (’ClonNat’, Werner BioAgents);
the presence of the genomic ΔF670/R1116T mutation
was confirmed by sequence analysis, creating strain RL4.
The endogenous YOR1 promoter was replaced with a
Tet-OFF regulatable element by insertion of pJH023, as
previously described [20], at the YOR1 locus to create
strain RL8. RL8 was mated to the MATa deletion strain
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Figure 1 Characterization of Yor1-ΔF/R1116T. (A) The initial characterization of YOR1 alleles was performed using plasmid-based mutagenesis. A
yor1 null strain, yor1-Δ0, was transformed with a plasmid control (pRS316), or plasmids expressing YOR1, yor1-ΔF670, or yor1-ΔF670/R1116T as indicated,
and the strains were serially diluted and spotted onto YPEG media with and without 0.2 µg/mL oligomycin. The yor1-ΔF670 mutation was associated
with a trafficking and pump defect that rendered it phenotypically equivalent to yor1-Δ0. However, an additional intragenic mutation, Yor1-ΔF670-
R1116T, exhibited an intermediate phenotype. (B) Capture of Yor1 into ER-derived transport vesicles was measured using an in vitro vesicle budding
assay that quantifies uptake of newly synthesized cargo proteins from radiolabeled permeabilized cells after addition of purified COPII proteins in the
presence (+) and absence (-) of GTP. Total membranes (T) were separated from the liberated vesicles by differential centrifugation. Packaging of Yor1
into the vesicle fraction was monitored by immunoprecipitation; Sec22 is a control cargo protein that demonstrates efficient vesicle production even
in the absence of packaging of the mutant forms of Yor1. Neither Yor1-ΔF nor Yor1-ΔF/R1116T were captured into COPII vesicles whereas wild-type
Yor1 was packaged normally. (C) Trypsin sensitivity of Yor1 was assessed by limited proteolysis of microsomal membranes expressing wild type and
mutant forms of Yor1. Increasing concentrations of trypsin were added as indicated prior to processing of membranes for immunoblot analysis. Wild-
type Yor1 is cleaved to several stable bands whereas both Yor1-ΔF and Yor1-ΔF/R1116T were significantly more susceptible to proteolytic attack. (D)
Cross-linking between transmembrane domains of Yor1 was measured following introduction of paired cysteine substitutions into wild-type and
mutant Yor1 as indicated. Addition of increasing concentrations of cross-linker resulted in the accumulation of wild-type Yor1 in a cross-linked species
with distinct gel mobility. Cross-linking of Yor1-ΔF and Yor1-ΔF/R1116T resulted in the disappearance of the non-cross-linked species and the
appearance of high molecular weight aggregates, suggesting abnormal assembly of transmembrane domains in these mutants. (E) Yor1 stability was
monitored by pulse-chase analysis. Cells expressing wild-type or mutant forms of Yor1 were radiolabeled for 10 min, and then chased for 180 min with
non-radioactive amino acids. The amount of Yor1 present at each time point was determined by immunoprecipitation and autoradiography (top
panel). The percentage of Yor1 remaining was calculated relative to the starting material at t = 0 (bottom panel). (F) Yor1 function was probed using a
rhodamine-pumping assay. Yor1-Δ0/Pdr5-Δ0 cells carrying the indicated Yor1 alleles on a plasmid were loaded with the fluorescent dye, rhodamine,
and the amount of fluorescence released over time into the culture supernatant was measured. The Yor1-ΔF670-R1116T mutation was associated with
rhodamine extrusion intermediate between that of the wild-type Yor1 allele and either the Yor1-Δ0 or Yor1-ΔF670 mutant forms (which were
functionally equivalent in this assay, as in the oligomycin resistance growth phenotype assay).
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collection and double mutants selected by the synthetic
genetic array (SGA) method [11].
Yeast media
For SGA [11], media was prepared with the following
modifications. Mating was carried out in YPD liquid fol-
lowed by diploid selection in YPD containing G418 and
ClonNat, and a second round of diploid selection sub-
stituting Pre-Spo media 5 for YPD as described [21].
Cultures were sporulated at room temperature for 1 week,
before two rounds of transfer to haploid double mutant
selection media [11]. For Q-HTCP, YPEG media (10 g/L
yeast extract, 20 g/L peptone, 3% ETOH, 3% glycerol, and
1.5% agar) was used with 2 ng/mL doxycycline and con-
centrations of oligomycin ranged from 0.05 to 0.25 ug/mL
for yor1-ΔF strains, and 0.05 to 0.35 ug/mL for YOR1
strains. Doxycycline was used at 2 ng/mL to optimize the
expression level of Yor1-ΔF for phenotypic screening to
detect enhancers and suppressors at the indicated concen-
trations of oligomycin.
Cell proliferation measurements and quantification of
gene interaction
Cells were inoculated from glycerol stocks in a 384 well
format and grown for 36 to 48 hours in YPD with G418
(200 ug/mL) and ClonNat (100 ug/mL), and without
doxycycline. Overnight-grown cell arrays were spotted
to agar plates using a 384-pin tool (FP6 pins from V-P
Scientific) after first transferring to a ‘dilution plate’ to
reduce the number of cells transferred, as described pre-
viously [13]. Quantitative high throughput cell array
phenotyping was used to obtain growth parameters by
time lapse imaging of cell arrays and fitting to a logistic
growth equation (Figure 2B), as described previously
[13,14]. The parameter L, which is equivalent to the
time at which half the final carrying capacity is reached,
was used to quantify interactions (Figure 2C). The
growth curve parameters obtained from the fitted curves
are provided in Additional File 1. Interactions were
quantified on the basis of a change in the response to
oligomycin attributable to a gene deletion (Figure 2D),
where interaction strength is a function of oligomycin
response as determined by departure of the L value for
a given double mutant strain vs. the Yor1-ΔF single
mutant across all oligomycin concentrations. To com-
pute the interaction strength, the following algorithm
was used to determine the difference between each dou-
ble mutant and the yor1-ΔF670 single mutant:
Yi = Observed growth parameter for the knockout at
dose i (Di)
Ki = the effect of the knockout and its interaction with
yor1-ΔF at a dose of oligomycin
K0 = the effect of knockout when no oligomycin is
present (D0)
Li = the interaction effect of a knockout with yor1-ΔF
at each dose of oligomycin
1. Compute the average value of the 768 reference
cultures at (Di): RDi,
To simplify visualization of the interaction graphically,
2. Remove the dose effect to oligomycin on the refer-
ence: Ki = Yi - RDi
3. Remove the effect of knockout (K0) when no oligo-
mycin is present (D0): Li = Ki - K0
Therefore L0 = 0 by definition.
4. Fit a quadratic curve: Li = A + B*Di + C*Di
2
5. Compute the interaction value at the max dose:
Li-max= INT = A + B*Dmax + C*Dmax
2
Positive interaction values, termed ‘deletion enhan-
cers’, denote increasing L and thus indicate exacerbation
of the growth delay induced by oligomycin. For deletion
strains failing to grow at the higher concentrations of
oligomycin, interactions were ranked in tiers, with the
strains failing to grow at a greater number of concentra-
tions grouped as stronger deletion enhancers (Addi-
tional File 1). Conversely, strains that grew faster
(shorter time to reach L) had negative interaction values
and we refer to loss of the gene having a ‘deletion sup-
pressor’ effect on the oligomycin sensitivity phenotype.
Interaction plots for each gene deletion strain in both
the context of wild-type YOR1 and yor1-ΔF670/R1116T
expression are given in Additional Files 2 and 3. The
graphs are ranked by the interaction strength of the
yor1-ΔF670/R1116T allele. To help further partition the
list of genes influencing the yor1-ΔF/R1116T phenotype,
gene-drug interaction data were incorporated with the
primary screen data for clustering (described below). For
gene-drug interactions, the number of concentrations of
each drug tested was too few to fit a quadratic, thus
each perturbation was considered separately and interac-
tions were quantified as the difference between the dele-
tion and the wild-type reference strains and plotted after
adjusting for the dose effect of oligomycin and the effect
of the deletion on growth in the control media. The inter-
action data submitted to BioGRID [22] for inclusion in the
BioGRID database and SGD [23] are indicated in Addi-
tional File 5 in column L of the worksheet ‘REMc_data
and clustering’.
Recursive expectation-maximization clustering (REMc)
Interaction values selected for clustering represented the
union of genes from the yor1-ΔF670/R1116T screen with
interaction values >10 or <-16 and the screen with wild-
type YOR1 in the same background with interaction values
>10 or <-12. These thresholds were chosen to represent
the tails of the distributions of interaction strength.
Among deletion strains not growing at one or more con-
centrations of oligomycin, higher interaction values were
assigned for cultures that failed to grow at lower concen-
trations (see Additional File 5). Gene-drug interaction data
were incorporated to create profiles for genes selected
from the primary screen, as previously described [13].
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Figure 2 A genome-wide screen for Yor1-ΔF gene interaction. (A) Time-lapse imaging was used to measure the growth phenotypes of
haploid double mutants. Shown are example spot cultures (time indicated below each image) for strains with deletion suppressor and deletion
enhancer effects on oligomycin sensitivity, along with a yor1-ΔF single mutant control, grown on media containing 0.2 μg/mL oligomycin. (B) To
quantify phenotypes, spot culture image series were analyzed for pixel density and fit to a logistic growth equation [14]. See Materials and
Methods and Additional File 1 - Discussion B for further details. (C) Multiple concentrations of oligomycin were used to assess the interaction
strength for each gene deletion, using the growth parameter, L, corresponding to the time at which a culture reaches its half maximal density,
K (r denotes the maximum specific rate). Gene deletion suppressor effects (interactions reducing L) are highlighted in green, whereas gene
deletion enhancer effects (interactions increasing L) are indicated by blue. The three panels contain growth curves for the deletion strains shown
in panel A at different oligomycin concentrations (0, 0.15, and 0.25 μg/mL). G(t) is the logistic fit for the data obtained for each culture time
series; raw values for culture growth are indicated by black circles (WT/Ref), green squares (hlj1-Δ0 strain), and blue triangles (sop4-Δ0 strain).
(D) Gene interaction is shown for hlj1-Δ0 (green squares) and sop4-Δ0 (blue triangles). Divergence of L for the double mutants is displayed as a
function of oligomycin concentration, compared to the phenotypic distribution of replicates of the yor1-ΔF670/R1116T single mutant (gray
diamonds represent the distribution of central 95% of L values for 768 single mutant replicates). The data for the double mutants were shifted
by their difference with the single mutant (median response) at the zero oligomycin concentration (filled symbols), correcting for growth
differences not attributable to oligomycin response. To quantify interactions, the data for each deletion mutant were first fit to a quadratic
equation, and then the difference between the deletion mutant and the reference median was taken at an indicated concentration of
oligomycin. To highlight the interactions, the raw data (left panel) were transformed to remove the oligomycin dose effect (right panel). (E) A
scatter plot of interaction scores for pairs of gene deletion strains with overlapping open reading frames (obtained at oligomycin = 0.25 µg/mL).
The open reading frames with a greater degree functional annotation in SGD were designated as the ‘ORFs’, and those with less functional
annotation designated ‘overlapping genomic regions’ [78]. (F) The affect of oligomycin dose on the growth curve parameters (left to right), L
(time to half carrying capacity, K (carrying capacity), and r (maximum specific rate), and the area under the curve (’A’), for 384 replicates of the
yor1-ΔF single mutant strain. Each diamond represents the central 95% of the standardized data for that oligomycin dose. The data for each
parameter at each dose was standardized (arbitrary units) by subtracting the mean and dividing by the standard deviation of the group not
treated with oligomycin. The oligomycin = 0 group is centered at 0. Using standard units for the data allows the dose trend between the panels
to be directly compared. The oligomycin dose effect is greatest for L, followed by AUC, and with minor effects on K and r.
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REMc was used to identify groups of genes having similar
interaction profiles [24]. To obtain a dendrogram and
finer grain view of each REMc cluster, hierarchical cluster-
ing using Euclidian distance and complete linkage was
performed using Matlab. For all heat maps, the order of
the perturbations is the same and labels indicate the inter-
action values from: (A) the yor1-ΔF670/R1116T/gene dele-
tion double mutants; (B) the screen of single-mutant
(wild-type YOR1 background) gene deletion strains; (C)
the growth defect of the deletion strain in Cold Spring
Harbor SC media [25]; gene-drug interactions on the fol-
lowing media (D) SC media lacking threonine (using
media in (C) as the reference); (E) SC media lacking threo-
nine and with 80 ug/mL beta-chloro-alanine (using media
in (D) as the reference); SC media supplemented with (F)
0.7 nM rapamycin; (G) 1.4 nM rapamycin; (H) 1 nM FK-
506; (I) 0.7 nM rapamycin and 1 nM FK-506; (J) 50 mM
hydroxyurea; (K) 125 mM hydroxyurea; (L) 75 ng/mL
cycloheximide; (M) 125 ng/mL cycloheximide; (N)
150 nM miconazole; or (O) 225 nM miconazole (see Addi-
tional File 5).
Gene homology mapping
The Princeton Protein Orthology Database [26] was used
to identify yeast-human homologs for relating the results
of our yeast screen to the larger literature of CFTR-ΔF508
protein biogenesis factors [27]. In cases where homology
was not one-to-one, the best functional matches were dis-
cussed [28]. For example, human isoforms of HSP90
(HSP90A and HSP90B) have opposite effects on CFTR-
ΔF508 biogenesis when knocked down by siRNA [16],
thus deletion of yeast HSP82, an HSP90 family member in
yeast that acts as a deletion suppressor, mimics only the
effect of siRNA knockdown of HSP90A. As another exam-
ple, yeast HLJ1 and three different homologous human
proteins (CSP, DNAJB12, and DNJB2) exert comparable
effects on Yor1-ΔF and CFTR-ΔF biogenesis, respectively
(see Additional File 1 - Discussion C).
Biochemical analysis of Yor1-ΔF670 and
Yor1-ΔF670/R1116T
In-vitro uptake of Yor1 into COPII vesicles was per-
formed from radiolabeled semi-intact cells, and limited
proteolysis, chemical cross-linking, and in-vivo pulse-
chase experiments were all performed as described [29].
Rhodamine efflux assay
yor1-Δ0/pdr5-Δ0 double mutant strains bearing plasmids
expressing YOR1 variant alleles (as indicated in Figure 1)
were grown to mid-log phase (OD600 of approximately
0.5) in SD-ura medium (0.67% yeast nitrogen base, 20%
glucose, -ura dropout mix). Cells equivalent to fifty
OD600 units were harvested, washed with 50 mM HEPES
pH 7.0, and loaded with rhodamine B (Sigma-Aldrich) by
incubating cells in 5 mL of 50 mM HEPES, pH 7.0,
5 mM 2-deoxyglucose, and 100 μg/mL rhodamine B for
2 h at 30ºC. Cells were washed and resuspended in 5 mL
of 50 mM HEPES, pH 7.0, supplemented with 10 mM D-
glucose (Sigma-Aldrich). Every 2 min, 500 μL aliquots of
cell suspension were removed, cells collected by centrifu-
gation, and the rhodamine-containing supernatant was
removed and quantified by measuring absorbance at
OD555.
siRNA experiments
For TTC35 mRNA knockdown experiments, HeLa cells
(CCL2, ATCC) were transfected with pcDNA-CFTR-
ΔF508 plasmids using TransIT-HeLaMONSTER® trans-
fection reagent (Mirus Bio, Madison, WI, USA) per
instruction manual. Cells were split into a 12-well plate
and the next day transfected with TTC35 specific siRNA
(sc-77588, Santa Cruz Biotechnology, Santa Cruz, CA,
USA) at 10 or 25 nM, using RNAiMAX (Invitrogen). As a
negative control siRNA, Stealth RNAi™ siRNA negative
control lo GC (Invitrogen, 12935-200) was used at 25 nM
final concentration. The next day, cells were moved to
27°C and incubated for an additional 72 h before harvest.
For western blot analysis, cells were lysed in RIPA contain-
ing Halt protease inhibitor cocktail (Thermo-Pierce), and
then analyzed on 4% to 20% gradient SDS-PAGE (Invitro-
gen). After blotting onto a PVDF membrane, the blot was
cut laterally into three pieces at 75kD and 35kD markers.
The top piece (>75kD) was developed for CFTR protein
(150 to 180 kD) using 3G11 rat monoclonal antibody [30]
, the middle piece (between 75kD and 35kD) was probed
for a-tubulin (approximately 55kD) as an internal control
(DM1A antibody, GeneTex), and the bottom piece
(<35kD) was probed with TTC35 antibody (sc-166011,
Santa Cruz Biotechnology). Blots were developed using
SuperSignal West Pico Chemiluminescent substrate
(Thermo-Pierce), and exposed to Kodak BioMax MR film.
Densitometry was performed using ChemiDoc XRS and
Image Lab software (BioRad).
Results
Yor1-ΔF and CFTR-ΔF are membrane proteins with
shared biogenesis defects
Yor1 is a close homolog of CFTR in the ATP-binding
cassette family of membrane transporters that includes
pleiotropic drug transporters [31], and it is the primary
determinant of oligomycin resistance due its plasma
membrane-localized function in extruding oligomycin
from the cell [32]. Analogous to CFTR-ΔF508, mutation
of the highly conserved phenylalanine residue in the
first nucleotide binding domain, Yor1-ΔF670, results in
ER-retention and degradation by proteolysis, yielding an
oligomycin-sensitive phenotype [13]. However, unlike
CFTR-ΔF508, Yor1-ΔF670 appears not to retain residual
membrane transport function [8]. Therefore, we per-
formed an intragenic suppressor screen and identified a
second site mutation (R1116T) that restored partial pump
function (Figure 1 and Additional File 1 - Discussion A).
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The oligomycin growth phenotype associated with Yor1-
ΔF670-R1116T was intermediate between that of Yor1-
ΔF670 (which was indistinguishable from the yor1-Δ0
deletion mutant) and wild-type Yor1 (Figure 1A). The
intracellular fate of the partially functional R1116T mutant
was identical to that of the original Yor1-ΔF mutant: the
protein was less efficiently packaged into transport vesicles
reconstituted in vitro (Figure 1B), Yor1-ΔF670-R1116T
was misfolded, as detected by limited proteolysis (Figure
1C) and intramolecular cross-linking (Figure 1D), and
turnover was indistinguishable from Yor1-ΔF670 by pulse-
chase analysis (Figure 1E). We assessed the effect of the
R1116T mutation on pump function using a rhodamine
exclusion assay, which revealed partial rescue of Yor1-
ΔF670-R1116T relative to Yor1-ΔF670 (Figure 1F).
Although we do not know the precise mechanism by
which the R1116T mutation impacts the activity of Yor1-
ΔF, the aggregate of our evidence suggests that it is a
dominant gain-of-function mutation that confers addi-
tional drug-pumping activity (see Additional File 1 - Dis-
cussion A and Additional file 1, Figure S1 for further
description and characterization of the R1116T mutation).
The molecular characteristics and intermediate oligomycin
resistance conferred by Yor1-ΔF670-R1116T (referred to
here forward as ‘Yor1-ΔF’) resemble the defects of CFTR-
ΔF508, and thus provided a model to screen the yeast gen-
ome for canonical protein regulators of ‘ΔF-associated’
biogenesis by introducing yor1-ΔF into the yeast gene
deletion strain collection [10,11].
Measurement of gene interaction strength from growth
curves
For quantitative phenotypic analysis of the genomic col-
lection of deletion strains, we used growth curve analysis
at multiple concentrations of oligomycin, and examined
the entire library alternatively in the context of expres-
sion of Yor1-ΔF or Yor1 wild-type protein. The phe-
nomic method of time series analysis of cell array
images (Figure 2A) provides growth curves on a geno-
mic scale for measuring strength of gene interaction
[13]. The kinetic analysis is based on density of each
spot culture over time [13,33], in contrast to qualitative
methods or quantitative strategies that employ single
time points of culture area [34,35]. Q-HTCP, by virtue
of imaging cultures arrayed on agar rather than measur-
ing optical density of liquid cultures in multi-well plates,
provides orders of magnitude greater throughput, with
spot density time series for each strain (Figure 2A) that
fit to a logistic growth equation (Figure 2B) [14]. We
used a parameter from the curve fitting to quantify each
gene interaction by comparing growth inhibition
between the Yor1-ΔF single mutant and each respective
double mutant across multiple oligomycin concentra-
tions (Figure 2C).
In this study, we focused on a specific parameter of
logistic growth, termed L, which represents the time it
takes a culture to reach half its final density, K [14] (Addi-
tional File 1 - Discussion B). Thus, the L parameter is
inversely proportional to fitness, such that double mutant
strains exhibiting a shorter L relative to the yor1-ΔF single
mutant (that is, deletion suppressors of the oligomycin
sensitivity phenotype) indicate genes that (when present)
function to prohibit biogenesis of misfolded Yor1-ΔF.
Conversely, gene interactions resulting in a longer L (that
is, deletion enhancers) correspond to candidates that nor-
mally promote Yor1-ΔF biogenesis (Figure 2C). The null
hypothesis for gene interaction [36] was defined by a neu-
trality function consisting of the median L value from
replicate cultures of the Yor1-ΔF single mutant across
increasing oligomycin concentration, to account for the
drug effect. In addition, to account for the gene deletion
effect on growth (independent of oligomycin treatment)
the L value of each double mutant culture was adjusted
(for every oligomycin dose) by the constant difference
between it and the Yor1-ΔF reference mutant median at
the zero-oligomycin concentration (Figure 2D, left panel).
Next, a quadratic equation was fit to the L-value differ-
ences for each double mutant over all oligomycin concen-
trations. The difference between this quadratic fit and the
reference median at the highest concentration of oligomy-
cin having measurable growth was defined as the interac-
tion score (enhancing interactions were further ranked
according to the number of oligomycin concentrations
where growth was completely inhibited). To more clearly
visualize only the interactions, the data were transformed
to remove the dose effect of oligomycin on the yor1-ΔF
single mutant cultures (Figure 2D, right panel).
Our screen, by virtue of incorporating multiple con-
centrations of oligomycin and examining the trend of
response, contains an intrinsic form of replication. The
consistent trends of phenotypic response observed
serves as evidence of technical reproducibility in the
phenotypic analysis. We also repeated the entire screen
at all concentrations, which again indicated high repro-
ducibility (Additional file 1, Figure S2).
Reproducibility of the gene interaction measurements was
further evidenced by positive correlation between values
obtained for deletion strains that shared chromosomal
strand overlap in their open reading frames (Figure 2E). To
assess this type of correlation, each overlapping ORF pair
member was assigned to one of two groups according to it
being the ‘better’ or ‘less well’ annotated gene/orf. Less well-
annotated orfs would, for example, include computationally
determined chromosomal regions that were systematically
knocked out by the Yeast Gene Deletion Consortium, but
do not necessarily encode expressed genes [37]. Stronger
interactions tended to correlate with the extent of gene
annotation, perhaps due to residual functional activity in
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the non-overlapping regions of the better annotated
genes that were not deleted by removal of overlapping
ORFs (Figure 2E). The phenotypic parameter, L, which we
used in this study to quantify interactions was more sensi-
tive to detect the growth inhibitory effect of oligomycin
(Figure 2F). This is the first study we are aware of demon-
strating the utility of genome-scale growth curve acquisition
and use of the L parameter for quantitative assessment of
gene interaction in phenomic analysis.
Detection of molecular mechanisms associated with weak
gene interaction
We found yor1-ΔF gene interaction to occur abundantly,
across the genome and with wide-ranging strengths of
effect. To help clarify the many interactions, we performed
a similar analysis of oligomycin growth inhibition in the
gene deletion strain collection endogenously expressing
wild-type YOR1 (Figure 3). The comparison of Yor1 and
Yor1-ΔF candidate regulators was focused on four general
classes: those that impact (positively or negatively) only
Yor1-ΔF, and those that impact (positively or negatively)
both wild-type and the misfolded form of Yor1. Each class
of mutant holds potential for uncovering novel mechanis-
tic insight into biogenesis of topologically complex mem-
brane proteins. Yor1-ΔF-specific interaction suggests
pathways that recognize the misfolded protein, whereas
interaction with both the misfolded and wild-type forms
of the protein could represent either proteins that gener-
ally influence ABC transporter biogenesis or genes that
affect oligomycin resistance independent of Yor1 function,
such as pleiotropic drug resistance (PDR) genes or mito-
chondrial components (Figure 3).
Given the high sensitivity of the cell array method for
measuring gene interaction, we sought perspective as to
whether weak interactions reflected effects on Yor1 bio-
genesis that could be detected with molecular assays.
Cue1 is an ER membrane protein that serves to recruit the
ubiquitin-conjugating enzyme, Ubc7, to the ER, where it is
required for ubiquitination of misfolded proteins prior to
their disposal by proteasome-mediated ER-associated
degradation. Rpn4 is a transcription factor that activates
expression of proteasome genes; the depletion of protea-
some subunits in an rpn4-Δ0 null strain would be
expected to impair ER-associated degradation of misfolded
proteins, potentially increasing their biogenesis. Yor1-
ΔF670 turnover has been previously reported as dimin-
ished by mutation of UBC7/QRI8 [8,9]. Therefore, we
examined Yor1-ΔF670 stability in the functionally related
cue1-Δ0 and rpn4-Δ0 mutants, which showed weak inter-
action (Figure 4A, B). The half-life of Yor1-ΔF670 was
indeed prolonged in both the cue1-Δ0 and rpn4-Δ0 strains
relative to wild type (Figure 4C, D). Thus, the screen was
sensitive to genes affecting proteasome-mediated turnover
of Yor1-ΔF670, validating the yeast model with respect to
this aspect of CFTR-ΔF biology [38,39] and confirming
the molecular basis of phenotypic effects revealed by the
screen.
Genes interacting with Yor1-ΔF map to homologous
regulators of CFTR-ΔF508
An open question is the extent to which gene interac-
tion is evolutionarily conserved, and thus the extent to
which simple genetic systems like yeast can reveal prin-
ciples about gene interaction relevant to human disease
[5]. A study comparing worms and yeast concluded
gene interaction lacks conservation [40], whereas studies
comparing evolutionarily divergent yeast have found
that substantial conservation exists [41,42]. However,
previous studies were not designed to model a specific
disease-related mutation. Our data represented an
opportunity to probe conservation of gene interaction
within a clearly defined molecular and cellular context,
namely biogenesis of homologous ABC proteins carrying
mutation of a conserved disease-causing residue
[5,13,14].
To assess relevance of our dataset to CFTR-ΔF bio-
genesis, we surveyed the literature for evidence of evolu-
tionarily conserved cellular responses to the ‘ΔF-like’
folding defect. The (P-POD) [26] was used to identify
homologous genes [27], yielding many examples of func-
tional concordance between biogenesis factors for Yor1-
ΔF and those known for CFTR-ΔF (Figure 5A). Most
CFTR-ΔF protein regulators have been characterized
using RNAi methods aimed at identifying targets for
increasing CFTR-ΔF processing by small molecule inhi-
bitors [15,16]. Accordingly, the majority of homologous
yeast gene deletions found to modulate Yor1-ΔF biogen-
esis also functioned to enhance biogenesis. Broadly
defined functional categories highlighted the shared
fates of Yor1-ΔF and CFTR-ΔF, falling into at least
three classes including (Figure 5A and Additional File 1
- Discussion C): Syntaxins, which mediate vesicle fusion
within the secretory pathway and may also regulate
CFTR channel activity more directly [43-46]; Rab pro-
teins, which regulate vesicular trafficking of CFTR-ΔF
and other plasma membrane proteins [47,48]; and ER
quality control machineries, a class of regulators of that
encompasses chaperones and other machineries that can
influence folding and ER-associated degradation (ERAD)
to govern the fate of misfolded proteins in the ER
[16,49-52]. Each of these regulator classes exhibited
homologous genes that encode regulators of CFTR-ΔF
biogenesis (see Additional File 1 - Discussion C for
further explanation of homologies). Moreover, because
the homologous regulators were not the strongest in
effect from the overall screen, additional conserved reg-
ulators were likely identified (Figure 5B). Together,
these results indicate evolutionary conservation of gene
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interaction and suggest novel interactors from the Yor1-
ΔF screen may represent as yet uncharacterized modi-
fiers CFTR-ΔF biogenesis.
Identification of functional gene modules by clustering
analysis
We used REMc to search for functional gene modules
[24]. Gene profiles selected for clustering had Yor1-ΔF
interaction scores >10 or <-16, or in the context of
wild-type Yor1 had gene-drug interaction >10 or <-12.
We created interaction profiles for each gene by includ-
ing additional gene-drug interaction data, and then
assessed modularity (similar influence on the phenotype
across different perturbations) by clustering [13,53,48].
The REMc algorithm objectively specified the number
of clusters and provided an indication of cluster quality
[24]. We used the GOid_z method to quantify overall
enrichment of gene ontology (GO) functional informa-
tion within clusters [24]. GOTermFinder, was used to
identify specific terms associated with each cluster as
well as the representative genes [54]. All clusters were
enriched for functional information and many were
associated with specific GO terms (Additional File 1 -
Table S1 and Additional File 5). We also note that some
functionally related genes appeared in different clusters,
even though they exerted similar effects on Yor1-ΔF
0
10





























Figure 3 Gene-gene interaction with Yor1 and Yor1-ΔF serves as a resource for identification of novel regulators of membrane
protein biogenesis. Interaction scores for individual yeast mutants in the context of either wild type Yor1 (x-axis) or Yor1-ΔF (y-axis) were
plotted to illustrate classes of protein biogenesis regulators suggested by the screen. Deletion enhancers (positive value indicates prolonged L
and slower growth) and suppressors of oligomycin sensitivity represent factors predicted to promote or prohibit protein biogenesis, respectively.
Interactions along the y-axis may indicate proteins that act more specifically on misfolded proteins, while those in the upper right and lower left
quadrants are considered to have more general effects on Yor1 protein biogenesis, or to affect the phenotype independently of Yor1/Yor1-ΔF.
Examples of genes with functions suspected to directly influence oligomycin resistance, without necessarily acting through Yor1 biogenesis are
denoted by ‘x’. EMC members are colored in burgundy. CUE1, RPN4, and ERV14 are other genes that were further validated by molecular studies
(see Figures 4, 6, and 7).
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biogenesis (for example, the EMC genes described
further below). This suggests that though they cooperate
to determine the fate of Yor1-ΔF, they can function differ-
entially in other cellular contexts. Other explanations for
the appearance in different clusters of genes known to be
functionally related include over-estimation of the number
of clusters, measurement error, and the gene-specific func-
tional relevance of particular gene interaction profiles
selected for clustering.
Validation of Erv14 as a cargo-specific sorting factor
for Yor1
Cluster 2-0.1-1 contained genes previously shown to
function cooperatively in protein transport through the
secretory pathway (Figure 6A). Namely, Sys1, Mak3, and
Mak10 cooperate in the recruitment of the ARF-like
GTPase, Arl3, to the Golgi to regulate vesicular trans-
port [55]. Given the clustering of these gene interaction
profiles with Erv14, which can function as a cargo adap-
tor for enrichment of newly synthesized proteins into
ER-derived transport vesicles, we suspected they may
function in a common pathway, with Erv14 acting in an
upstream compartment distinct from the others in the
cluster (Figure 6B). Moreover, we observed oligomycin
sensitivity to be more strongly dependent on ERV14 in
the context of wild-type Yor1 than Yor1-ΔF (Figure 6C).
This difference raised the possibility that Erv14 pro-
motes capture of wild-type Yor1 into ER-derived trans-
port vesicles [56] more efficiently than it does for the
misfolded Yor1-ΔF substrate. According to this hypoth-
esis, reduced recognition of the misfolded Yor1-ΔF by
Erv14 would lessen the phenotypic impact of the erv14-
Δ0 null allele on oligomycin sensitivity in an allele-
specific manner (Figure 6C). We tested Erv14 function
by in vitro reconstitution of COPII vesicle formation
[57], comparing capture of Yor1 in the presence or
absence of Erv14. Indeed, ERV14 deletion specifically
reduced capture of Yor1, leaving a control cargo, Sec22,
unaffected (Figure 6D). Yor1-ΔF capture was weak
regardless of ERV14 status. Thus the gene-drug interac-
tion between erv14 and oligomycin can be explained by
a physical interaction between Erv14 and Yor1 that pro-
motes ER export. Accordingly, our vesicle budding assay
revealed no defects associated with capture into ER-derived
vesicles in sys1-Δ0, arl3-Δ0, mak3-Δ0, and mak10-Δ0
















































































Figure 4 Molecular validation of weak gene interactions. (A) Ranking of interaction strength shows the distribution of phenotypic influence
of deletion mutants. Some physiologically relevant hits (for example, UBC7/QRI8) fell below our clustering thresholds of >10 or <-16 (blue and
green shading, respectively); the related components, CUE1 and RPN4, were on the cusp of our threshold but were still functionally relevant.
(B) The cue1-Δ0 and rpn4-Δ0 strains showed deletion suppressor phenotypes specific for yor1-ΔF (at right), since the single mutant (that is, in the
context of wild-type Yor1) did not affect oligomycin resistance. (C) By pulse-chase analysis, Yor1-ΔF turnover was reduced in the cue1-Δ0 and
rpn4-Δ0 backgrounds relative to the wild-type background. Maturation of a control protein, Gas1, was unaffected. (D) Quantification of three
replicates of the experiment shown in Figure 2B; error bars represent standard deviation.
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and molecular data suggest this cluster of genes functions
as a linear pathway to regulate progress of Yor1 out of the
ER and through the Golgi for delivery to the plasma
membrane.
An ER membrane complex discovered in yeast promotes
biogenesis of CFTR-ΔF
In light of homologous genes exerting analogous influ-
ences on Yor1-ΔF in yeast and CFTR-ΔF processing in
Syntaxin Module:
Yeast gene    Human homolog
SSO2      STX1a
VAM7      STX8
SNC1      VAMP8
TLG2      STX16
Rab Module:
Yeast gene    Human homolog
VPS21      RAB5
YPT7      RAB7
MYO4      MYOSIN-5
ER Quality Control Module:
Yeast gene    Human homolog
SSA2      HSPA8
HSP82      HSP90A
HLJ1      DNAJC5/CSP
HLJ1      DNAJB12
TOM1      HACE1


































EMC1 EMC4 ERV14 EMC5 SOP4 EMC2 EMC3 EMC6 YDJ1




















Figure 5 Modulation of CFTR-ΔF and Yor1-ΔF biogenesis occurs via homologous gene interaction. (A) At left, gene interactions are
illustrated by plotting the parameter L vs. oligomycin concentration (increasing upward: 0, 0.05, 0.1, 0.15, 0.2, and 0.25 µg/mL) for the double
mutant and the full distribution of 768 Yor1-ΔF single mutant cultures (gray diamonds). Leftward departure indicates faster growth and
improved biogenesis of Yor1-ΔF. At right, human genes found in the literature to modulate CFTR-ΔF biogenesis are paired with homologous
yeast genes. Gene pairs are grouped into protein classes associated with discrete cellular functions (see text and Additional File 1 - Discussion C).
(B) The strength of gene interaction is depicted with respect to chromosomal position and highlighted gene interactions indicate those
discussed in the manuscript (interactions are calculated at an oligomycin concentration of 0.2 µg/mL). Vertical lines demarcate chromosomes.
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human cells, respectively, we anticipated other yeast
gene interactions identified by our screen would simi-
larly represent homologs that function as conserved,
uncharacterized CFTR-ΔF modulators. Our attention
was drawn to a cluster (2-0.3-1) that contained EMC1,
EMC3, and EMC5, three components of a recently
described ER membrane complex [58]. Three additional
members of this complex, EMC2, EMC4, and SOP4
grouped together in cluster 2-0.2-0 (Figure 7A). All
seven of the EMC members were deletion enhancers
with interaction specificity for the Yor1-ΔF mutant pro-
tein (Figure 7B), and all had comparable strengths of
effect, suggesting removal of any one of the genes dis-
rupts a function common to all [13,35].
The molecular function(s) of the EMC are only begin-
ning to be characterized. Deletion of EMC3 (but not other
EMC members) activated an unfolded protein response
element (UPRE)-GFP reporter in a genome-wide screen,
which led to identification of the complex. However, the
EMC effect on Yor1-ΔF biogenesis appeared to be inde-
pendent of any association with induction of the UPR,
because deletion of HAC1 or IRE1 (which blocks the UPR)
exerted no effect on oligomycin resistance, and there was
very weak association between the strength of UPR activa-
tion and the influence of Yor1-ΔF biogenesis given the
same gene deletion [58,59] (Additional file 1, Figure S3).
Alternatively, EMC components might directly promote
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a b c ed f g h i j k l m n o
Figure 6 ERV14 promotes capture of Yor1 into COPII vesicles. (A) The genetic interaction profile of the erv14-Δ0 strain clustered with those
for the sys1-Δ0, arl3-Δ0, mak3-Δ0, and mak10-Δ0 strains. Columns represent diverse gene-drug interactions as described in methods. (B) Based on
known data [55], and supported by our phenotypic and molecular findings, Erv14, Sys1, Arl3, Mak3, and Mak10 appear to function in a pathway
with Erv14 acting in the ER and Sys1, Arl3, Mak3, and Mak10 functioning in the Golgi. (C) Gene-oligomycin interactions for erv14-Δ0 strains, in the
context of either wild-type Yor1 or Yor1-ΔF, suggested Erv14 promotes the biogenesis of both Yor1 and Yor1-ΔF. (D) Packaging of wild-type
Yor1 into COPII vesicles was quantified using an in-vitro budding assay that measures capture of newly synthesized cargo proteins from radio-
labeled permeabilized cells after addition of purified COPII proteins in the presence (’+’) or absence (’-’) of GTP [9], followed by
immunoprecipitation of the cargo protein of interest. ‘T’ indicates the total membrane pool of labeled Yor1-HA. Erv14-containing membranes
showed approximately four-fold more efficient capture into vesicles of HA-tagged Yor1 than erv14-Δ0 membranes. The defect showed specificity,
since ERV14 deletion did not affect packaging of another cargo protein, Sec22. Quantification of three independent experiments is shown at
right; error bars represent standard deviation. (E) Similar vesicle budding assays from mak10-Δ0, sys1-Δ0, and arl3-Δ0 membranes showed no
defects in Yor1 capture into COPII vesicles in these mutants, suggesting they function downstream of Erv14.
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a b c ed f g h i j k l m n o
Figure 7 A conserved ER membrane complex discovered in yeast promotes CFTR-ΔF biogenesis. (A) Six of seven members of the
recently described ER membrane complex (EMC) fell into two clusters (EMC genes are labeled in red; ‘EMC1 o/l’ indicates YCL046w, which
overlaps EMC1/YCL045c). Columns represent different gene-drug interactions as described in methods. (B) The interaction plots for EMC genes
(corresponding to genes in panel A) suggested the complex has a pro-biogenesis effect specific for Yor1-ΔF. The similarity in profiles is
consistent with the hypothesis that each EMC gene is required for the function of the complex in promoting Yor1-ΔF biogenesis. (C) By pulse
chase analysis, deletion of SOP4 did not affect the half-life of Yor1-ΔF670. Quantification of three independent experiments is shown; error bars
represent standard deviation. (D) Yor1-ΔF670 synthesis was reduced in the sop4-Δ0 strain based on the total amount of 35S-Met/Cys incorporated
during the initial 10-min pulse. Three independent experiments were quantified; error bars represent standard deviation. Wild-type Yor1 and the
GPI-anchored protein, Gas1, were unaffected by SOP4 deletion. (E) TTC35, the human homolog of EMC2, is required for normal biogenesis of
CFTR-ΔF. HeLa cells, transiently expressing CFTR-ΔF at 27°C, were co-transfected with control siRNA, 10 nM TTC35 siRNA, or 25 nM TTC35 siRNA
as indicated. Protein levels of TTC35, CFTR-ΔF, and a-tubulin were monitored from whole cell lysates by western blot, and (at right) relative
abundance from three independent experiments was quantified by densitometry; error bars represent standard deviation, significance was
assessed by a paired two-tailed t-test.
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in ER retention of Yor1-ΔF specifically, followed by
ERAD-mediated degradation, with reduced delivery and/
or stability at the plasma membrane. However, pulse-
chase analysis revealed that the Yor1-ΔF half-life was not
altered in EMC mutants (Figure 7C and data not shown).
Instead, we observed that less Yor1-ΔF was synthesized in
the initial 10-min pulse-labeling period when SOP4, a
member of the EMC, was deleted (Figure 7D). Reduced
labeling without increased degradation suggested a role
for the complex in early stages of Yor1-ΔF biogenesis,
such as during synthesis and translocation through the
Sec61 translocation pore. Interestingly, this pro-biogenesis
effect seemed specific to the misfolded protein, since the
oligomycin phenotype associated with wild-type Yor1 was
unaffected by deletion of EMC genes (Figure 7B). Further-
more, wild-type Yor1 and an unrelated plasma membrane
protein, Gas1, were synthesized normally in the sop4-Δ0
mutant (Figure 7D).
Potential relevance of the EMC components to CFTR-ΔF
processing was suggested by CFTR protein-protein interac-
tion data indicating the homolog of EMC2, TTC35, physi-
cally associates with CFTR-ΔF but not wild-type CFTR
(see supplemental data of reference [60]). However, at the
time of that study, the EMC complex had not been charac-
terized and only one subunit of the complex was identified
by the interactome study. In contrast, we determined that
all of the subunits give the same quantitative strength of
interaction and cluster together in their phenotypic gene
interaction profiles across several chemical perturbations.
Thus our screen data provided a potential link between
two high impact studies involving the CFTR interactome
and the identification of the novel EMC complex [58,60].
To test for functional homology, CFTR-ΔF was monitored
by immunoblot in the context of a TTC35 knockdown by
siRNA. HeLa cells were transiently transfected with a plas-
mid expressing CFTR-ΔF, co-transfected with TTC35
siRNA or control siRNA, and shifted to 27°C. The shift
from 37°C to 27°C was to allow adequate rescue of CFTR-
ΔF protein so that we could see the detrimental impact of
losing function of a presumed pro-biogenesis factor. Addi-
tionally, keeping the cells at 37°C during the knockdown of
TTC35 provided elimination of CFTR-ΔF protein pools
prior to TTC35 knockdown and shift to conditions where
CFTR-ΔF biogenesis can occur. Under the experimental
conditions performed, knockdown of TTC35 reduced
CFTR-ΔF expression by 30% to 50% (Figure 7E and Addi-
tional File 1 - Additional file 1, Figure S4). Thus CFTR-ΔF
processing is dependent upon expression of TTC35, vali-
dating the prediction from the yeast data for EMC involve-
ment in biogenesis of ΔF-misfolded ABC transporters.
Discussion
Although it is well known that genes, proteins, and
pathways are conserved across evolution, conservation
of interactions between genetic pathways having the
potential to differentially regulate expression of pheno-
types is only just beginning to be characterized in model
systems [61,62]. Therefore, the clinical relevance of such
networks remains to be elucidated [5,63,64]. In this
regard, our data suggest the intriguing possibility that
quantitative phenotypic analysis of Yor1-ΔF gene inter-
action reports on a complex trait in yeast of relevance
to biogenesis of CFTR-ΔF508. Thus, evolutionary con-
servation is sufficient to usefully model human genetic
disease in yeast - at least in the case of CF. This opens a
door for efforts to dissect gene interaction underlying
phenotypic complexity through integration of yeast phe-
nomic data with human genetic data. A few clinically
relevant genetic modifiers of cystic fibrosis disease were
recently identified, however these variants are not sus-
pected to function in CFTR protein biogenesis pathways
[2]. The genetic interaction model we have developed
could be useful to mine CFTR-ΔF508 GWAS data for
variant alleles that that modulate disease through effects
on protein biogenesis. The Yor1-ΔF model suggests the
potential existence of a large number of such modifiers.
Thus, the yeast phenomic model may inform human
genetic studies, where systematic, comprehensive, and
quantitative analysis of gene interaction is of interest.
Furthermore, given the large number of interactions, it
will likely be important in the future to analyze higher
order epistasis networks (for example, comprehensive
three-way gene-gene-gene interaction experiments),
which is unforeseen employing human genetic data
alone.
The outbred genetic structure of human populations,
due to its combinatorial complexity, severely limits the
power to analyze phenotypes with respect to gene interac-
tion [65]. Thus, tractable yeast phenomic models could
provide a powerful and complementary tool for dissecting
disease complexity if the principle of evolutionary conser-
vation of gene interaction applies [5]. Our work provides
evidence in support of this concept, as we demonstrate
that gene interactions discovered from the yeast Yor1-ΔF
model resemble by homology gene interactions similarly
characterized for CFTR-ΔF biogenesis in human cell mod-
els. The findings support the notion that even when the
phenotypic manifestations of homologous gene interaction
appear unrelated (for example, oligomycin resistance in
yeast vs. maintenance of peri-ciliary fluid depth in lungs),
the principle network modulating the associated pheno-
types can nevertheless be similar [5,66].
We examined whether homologous modifiers of
CFTR-ΔF were among the stronger Yor1-ΔF interac-
tions (Figure 5B). Conserved interactions were not
necessarily the strongest overall, raising points for con-
sideration in future studies: (1) although strong hits
from genetic screens receive the most attention, weak
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and intermediate strength interactions are also impor-
tant for understanding the evolution of phenotypic var-
iation; (2) the throughput and precision of Q-HTCP,
which provides over 50,000 growth curves per experi-
ment, is an enabling technology to map disease-relevant
gene interaction networks, particularly regarding high
quantitative accuracy to detect weak and intermediate
strength interaction with high confidence; (3) high con-
fidence measures of gene interaction across the entire
genome will advance the opportunity to assess conserva-
tion of between homologs at a systems level to deduce
functional modules that are most rapidly evolving within
gene networks [42,67]; and (4) the elucidation of con-
served aspects of a ‘ΔF biogenesis network’ provides a
starting point to predict novel human homologs of
Yor1-ΔF regulators, and ultimately define higher-order
interactions from a gene network perspective [65,68].
Thus, the Yor1-ΔF phenomic model can serve in several
ways as a tool to discover and prioritize targets for ther-
apeutic development as well as potential modifiers of CF
disease severity.
We chose the CFTR-ΔF508 allele causing cystic fibrosis
as proof of principle for modeling a human disease-rele-
vant gene interaction network in yeast, because CFTR-
ΔF508 is arguably the best-characterized human genetic
disease mutation. However, we anticipate that other
CFTR mutations in addition to CFTR-ΔF508 as well as
other diseases entirely can be analogously modeled in
yeast to generate useful insight and new hypotheses as to
how networks of interacting genes might modulate dis-
ease expression. For diseases not having a single locus
that accounts for a high fraction of the phenotypic varia-
tion, the power of experimentally tractable yeast epistasis
models may be even more beneficial [65]. Furthermore,
yeast gene interactions also have been useful for uncover-
ing genetic modifiers of foreign proteins; in one example,
yeast gene interactions modulating alpha-synuclein toxi-
city uncovered homologs that functioned similarly in
animal models of Parkinson’s disease, even though alpha-
synuclein is not encoded by yeast genomes [69]. In a
second example, an informatics approach discovered
‘phenologs’, defined as overlapping sets of homologous
genes associated with diverse phenotypic outcomes
across various species, thus discovering novel genetic
relationships between diverse phenotypes. Multiple
predictions were validated experimentally, including
homologs of genes functioning in yeast cellular resistance
to HMG-CoA reductase inhibition influence angiogenesis
in Xenopus embryos [66]. In a third example, a genome-
wide screen revealed unexpectedly that threonine meta-
bolism is required to buffer a deficiency of dNTP
biosynthesis, through augmenting provision of metabolic
intermediates to overcome inhibition of a key enzyme,
ribonucleotide reductase [20]. Although threonine
biosynthesis does not occur in multicellular eukaryotes, it
was nevertheless shown that threonine catabolism is
required in a developmentally-regulated way for DNA
synthesis in mouse embryonic stem cells [70], and also
for maintenance of stem cell chromatin state through
S-adenosyl-methionine metabolism and histone methyla-
tion [71]. Our study, together with these and other mod-
els indicate the power and utility of yeast genetic screens
for generating useful new hypotheses about the role of
gene interaction in phenotypic diversity, including
human disease [5,72].
A novel aspect of the phenomic approach described
here is the acquisition and analysis of time series data
from proliferating cell arrays. These data fit well to a
logistic growth equation so that growth curve parameters
of individual cultures can be employed to precisely and
accurately quantify gene interaction (Figure 2). Coupling
this method with a gradation in perturbation states (for
example, multiple oligomycin concentrations) brings a
new level of resolution to the powerful S. cerevisiae
methods for analyzing gene interaction. Previous large-
scale gene interaction studies have used endpoint mea-
surements of phenotypes (for example, colony outgrowth
at one time point) and binary perturbation states, which
have less sensitivity for detecting gene interaction due to
lower precision and accuracy of quantifying growth phe-
notypes [36]. The enhancement in quantitative resolution
provided by Q-HTCP was significant, because many con-
served interactions were intermediate in strength, and
thus were more likely to have been missed by less quanti-
tative methods (Figures 3 and 4) [13]. The validity of
weak to intermediate strength interaction was further
clarified biochemically in several cases (Figures 4 to 7).
The finding that gene interactions with Yor1-ΔF recapi-
tulate homologous gene products interacting with human
CFTR-ΔF in mammalian cell-based studies provides evi-
dence that gene interaction networks can be conserved
over great evolutionary distances (Figure 5). Thus, despite
differential selective pressure that these distantly related
ABC transporters have been subjected to, the cellular con-
text in terms of interacting proteins that govern the bio-
genesis of Yor1 and CFTR is conserved and renders yeast
a useful and powerful model for cystic fibrosis. Although it
remains to be tested, we speculate that GWAS-based
efforts to identify genetic modifiers of human disease
could be aided by comprehensive and quantitative epista-
sis data from yeast models [2]. An integrative/comparative
approach could help prioritize findings diluted by multiple
comparisons from human genetic analysis. The yeast phe-
nomic model provides a biological framework for identify-
ing, within quantitative trait loci, candidate genes with
putative functions worthy of further study [73].
As another speculative example, it is plausible that
deficiency of a cargo adapter protein, such as from
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Erv14 deletion, could give rise to a CF-like phenotype
without mutations in CFTR itself (Figure 6). That Yor1
required an ER export adaptor was in fact somewhat
surprising, because we had previously correlated ER
export of Yor1 with interaction between a well-charac-
terized basic binding pocket on the surface of the vesicle
cargo adaptor, Sec24, and a di-acidic export motif on
Yor1 [9]. Thus a potential explanation for the present
study findings is that Erv14 facilitates the Yor1/Sec24
interaction. CFTR also employs a di-acidic motif, albeit
in a distinct domain from that of Yor1, and Erv14 is
well conserved in metazoans [74], and therefore a simi-
lar mechanism of ERV14 facilitating interaction during
capture into transport vesicles is plausible for selection
of CFTR into ER-derived vesicles, and remains to be
tested.
A potentially clinically relevant outcome of our study
was the discovery of a novel function for the recently
described ER membrane complex. The EMC was discov-
ered in a screen to find ER folding factors in yeast [58].
We now show that deletion of any one of the members of
the evolutionarily conserved protein complex yields a
quantitatively similar deletion enhancer phenotype with
respect to Yor1-ΔF biogenesis (Figure 7). Interestingly,
this interaction effect appears specific for the misfolded
protein only, as deletion of members of the EMC did not
affect oligomycin sensitivity in the context of wild-type
Yor1 expression. Further studies are needed to clarify
these findings, however we postulate a role for the EMC in
the early secretory pathway, and suspect it acts in a pro-
biogenesis manner as part of the co-translational mechan-
ism - perhaps for proteins prone to misfolding. We did
not see a role for the EMC proteins in protein turnover,
since the half life or Yor1-ΔF was identical either in the
presence or absence of their expression. Instead, we
observed in the sop4-Δ0 mutant a reduced rate of produc-
tion of Yor1-ΔF (Figure 7).
Consistent with the above hypothesis, it was previously
noted that deletion of the EMC proteins yields a genetic
interaction profile similar to over-expression of the sec61-
2 mutation; thus, deletion of the EMC mimics genetic per-
turbation of the Sec61 translocon. Furthermore, deletion
of UBC7 or CUE1 (genes functioning in ERAD) was
aggravating in combination with deletion of either the
EMC genes or sec61-2 overexpression [58,75]. Our inter-
pretation of these data is that EMC and Sec61 act in a
functionally distinct pathway from ERAD, pathways that
can buffer loss of one another [5,76]. Other evidence sug-
gesting a role for the EMC in the early secretory pathway
comes from a high content microscopy screen, which dis-
covered loss of the EMC causes increased ER retention of
the Mrh1-GFP fusion protein [77]. Importantly, we note
that the role of the EMC and other secretory protein bio-
genesis network factors appears cargo-specific, since other
factors that were found in the Mrh1-GFP screen exerted
qualitatively different effects in our Yor1-ΔF screen [77].
From a detailed comparison of our screen with the list of
genes described by Bircham et al. to be required for for-
ward transport of Mrh1-GFP, we noted that the EMC
genes and SOP4 were ΔF-specific deletion enhancers;
GYP1, RAV2, VAC14, and MON2 were ΔF-specific dele-
tion suppressors; PKR1 was a non-specific deletion enhan-
cer; and most other genes (GOS1, PEP4, SPF1, VPS51,
VPS53, VPS60, VTA1, YPT6, and OPI3) showed no effect.
Thus, while several genes were found in both studies, only
loss of function alleles of the EMC complex appeared to
have a consistent effect on prohibiting biogenesis of mem-
brane proteins. Furthermore, for Yor1, prohibited biogen-
esis was specific to the misfolded Yor1-ΔF.
To test whether the EMC functions in a conserved
manner as a pro-biogenesis factor for CFTR-ΔF, we
knocked down TTC35/EMC2 in transfected HeLa cells
expressing CFTR-ΔF under temperature rescue condi-
tions. Since we did not observe an effect of disrupting the
EMC on Yor1-ΔF turnover, but rather a defect in Yor1-
ΔF production, we tested for a pro-biogenesis function of
EMC2 on temperature-rescued CFTR-ΔF. We found that
loss of EMC2 reduced the steady state level of CFTR-ΔF,
consistent with our Yor1-ΔF findings. These results pro-
vide a strong rationale to utilize both yeast and human
cells to clarify the pro-biogenesis mechanism for the
EMC on ΔF-misfolded proteins (Figure 7).
In summary, the datasets provided here will serve as a
resource for further identification and prioritization
among candidate genes and pathways contributing to cel-
lular processing of misfolded proteins. Novel cellular
pathways in addition to the ones discussed, were sug-
gested by this study to be of importance for biogenesis of
misfolded ABC transporter proteins and include mRNA
processing (for example, SKI complex) and ribosome-
associated functions, both of which were strong Yor1-
ΔF-specific deletion suppressors. The similarity in their
impact on Yor1-ΔF biogenesis could occur by influencing
rates of translation and/or altering protein-folding
dynamics, although other mechanistic explanations are
plausible. Future studies will be required to clarify the
role of these and other genes in Yor1-ΔF biogenesis and
their potential relevance to CFTR-ΔF. Additionally, given
the abundance of pair-wise interactions revealed in our
study, three-way interaction analysis will become increas-
ingly important to understand functional hierarchies in
higher-order epistasis networks that modulate Yor1-ΔF
and, by extension, CFTR-ΔF protein biogenesis.
Conclusion
The Yor1-ΔF670 gene interaction network was found to
be representative of CFTR-ΔF protein regulators identi-
fied from human cell models. In addition, multiple new
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functional categories of proteins were found to modu-
late the activity of Yor1-ΔF, suggesting potential impor-
tance of their homologs for CFTR-ΔF biogenesis.
Validation of Yor1-ΔF interactors using biochemical
assays provided confidence in the functional significance
of the screening results, and led to the discovery that an
evolutionarily conserved ER membrane complex simi-
larly impacts biogenesis of Yor1-ΔF and CFTR-ΔF. The
overall result suggests quantitative phenotyping of dou-
ble mutant yeast expressing Yor1-ΔF is useful for mod-
eling an evolutionarily conserved gene interaction
network functioning to modulate CFTR-ΔF biogenesis.
The clinical relevance of the Yor1-ΔF gene interaction
network to cystic fibrosis remains to be established in
patients. Yet in principle, Q-HTCP affords a general plat-
form to leverage the power of yeast genetics for exploring
the influence of gene interaction using other yeast phe-
nomic models of disease. The approach could be
extended, for example, to other cystic fibrosis-relevant
mutations in Yor1, other molecular models of protein
misfolding related disease, and homologous mutations in
proteins covering a wide range of molecular functions
where the cellular basis of disease involves evolutionarily
conserved processes.
Supplementary information
There are five additional files. Additional File 1 contains
one table and four figures, as well as three supplemental
discussion sections. All of the interaction data are avail-
able in Additional Files 2, 3, and 4. REMc clustering
results are provided in Additional File 5, and high confi-
dence Yor1-ΔF interactions submitted to BioGRID are
indicated in column L of the ‘REMc_data and clustering’
worksheet. The criteria for selecting genes as high confi-
dence are described in the ‘readme’ page of Additional
File 5. Only high-confidence, manually reviewed interac-
tions (instead of all interactions beyond a certain quanti-
tative threshold) were submitted to BioGRID (http://
thebiogrid.org), for inclusion in the BioGRID database
and SGD (http://yeastgenome.org). Interactions that were
considered lower confidence were excluded based on cri-
teria such as a large effect of the gene deletion on growth
in the absence of oligomycin or if gene-drug interaction
occurred in the presence of wild-type Yor1 expression, or
if the dose response of interaction across all oligomycin
concentrations was not well fit to the quadratic equation.
Additional material
Additional File 1: This file contains three supplemental discussion
sections, one table and four figures.
Additional File 2: This file contains tables of screen-related data.
Two screens were performed in the genomic collection of non-essential
gene knockouts. One screen was with the unmodified collection
(wild-type YOR1 allele), and the other was with the yor1-ΔF allele that
was introduced by the SGA method. Results from each screen are given
in two sheets. The first sheets (named ‘_screen’) have columns indicating:
(A) the oligomycin concentration; (B) name of the ORF; (C) name of the
gene deletion; (D) area under the growth curve; (E) the carrying capacity
(’K’) from the logistic growth equation fit; (F) the rate (’r’) from the
logistic growth equation fit; (G) ‘L’ from the logistic growth equation fit;
(H) R-squared value indicating residual after logistic growth fitting; and (I-
N) upper and lower bounds (95% confidence intervals) on the logistic
growth curve parameters. The second sheets (named ‘_interactions’)
contain the following fields: (A, B) ORF and gene name for deletion
strain; (C) ‘ORF effect’- indicating the difference in L between the double
mutant and the median of 768 replicate yor1-ΔF single mutant cultures
grown in the absence of oligomycin; (D) the interactions quantified by
quadratic fitting of the difference in L between double mutants and the
median of 768 replicate yor1-ΔF single mutant cultures, across increasing
concentrations of oligomycin, and taking the difference at the highest
oligomycin concentration observed for the double mutant; and (E) the
number of high oligomycin concentrations where no growth was
observed for the deletion mutant (that is, deletion enhancer effects).
Additional File 3: This file contains graphs of oligomycin response
for deletion strains in background of wild-type YOR1 or yor1-ΔF,
searchable by gene and ORF names. The graphs are ordered by
descending interaction score for yor1-ΔF double mutants, grouped also
by the number of high oligomycin concentrations at which no growth
was observed (that is, from strongest deletion enhancer to strongest
deletion suppressor). ‘miss’ indicates the number of high oligomycin
concentrations at which no growth occurred; ‘ORF’ indicates the
difference in L between the deletion mutant and its wild-type reference
strain; ‘int’ is the interaction quantity at the highest oligomycin
concentration observed; ‘DR’ indicates the difference between the ranks
of the deletion mutant in each of the two screens to indicate differential
interactions in the context of wild-type Yor1 vs. Yor1-ΔF. The filled
symbols indicate the raw ‘L’ value at the zero-oligomycin concentration
for the deletion mutant, by which all L values for the deletion mutants
were adjusted to quantify the interaction. The gray diamonds represent
the 95% central distribution of 768 replicates of the reference strain, from
which the dose effect at each oligomycin concentration has been
removed.
Additional File 4: Like Supplemental Data File 2, this file contains
graphs of oligomycin response for deletion strains in background
of wild-type YOR1 or yor1-ΔF. Herein, less-interactive and non-
interactive genes have been included for completeness.
Additional File 5: This file contains input data used for REMc, REMc
results, and results of GO Term Finder analysis of REMc clusters.
The sheet ‘REMc_data and clustering’ contains the following columns of
data: (A) an arbitrary cluster # indicating discrete clusters for each gene;
(B) the ORF and (C) gene name for the deletion strain; (D) the root and
(E) round 1, (F) round 2, and (G) round 3 cluster names; (H-K and M-V)
the interaction values for each gene-perturbation combination, for which
the column labels are described in order in methods and materials;
column L contains gene interactors submitted to BioGRID. The sheet
‘cluster summary’ contains the following columns of data: (A) REMc
cluster ID; (B) the number of genes in the cluster; (C) the log-likelihood
of the cluster; (D) the GOid_z (Gene Ontology information divergence
score), a measure of functional enrichment (across all GO terms) among
genes in each cluster; (E) the number of enriched GO Terms for each first
round cluster; (G-K) REMc data for Round 2 clusters; (M-Q) REMc data for
Round 3 clusters. The sheet ‘GTF’ contains the following columns of data:
(A) REMc cluster ID; (B) ‘selective’ GO Terms, meaning terms empirically
chosen to highlight relatively specific cellular processes to which a small
number of gene functions is ascribed. These are highlighted as
hypothesis-generating terms worthy of further validation due to the
presence of multiple genes from the same biological module exerting
similar patterns of gene-gene and gene-drug interaction. Manual review
indicated in the ‘REMc_data and clustering’ sheet (column M) refers to
interactions that were filtered out before submission to BioGRID based
on inspection of the interaction graphs in Supplemental Data File 2 with
attention to the following criteria: (1) the oligomycin dose response was
uncharacteristic (for example, reaching a plateau); (2) the dose response
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was not well fit to the quadratic; (3) the Yor1-ΔF double mutant strain
was very slow growing in the absence of oligomycin; (4) the deletion
mutant in the context of Yor1 wild type suggested that oligomycin drug
interaction was independent of Yor1-ΔF expression; (5) weak effects.
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